KR900012919A - 벤조 융합된 n-함유 헤테로사이클 유도체 - Google Patents
벤조 융합된 n-함유 헤테로사이클 유도체 Download PDFInfo
- Publication number
- KR900012919A KR900012919A KR1019900001319A KR900001319A KR900012919A KR 900012919 A KR900012919 A KR 900012919A KR 1019900001319 A KR1019900001319 A KR 1019900001319A KR 900001319 A KR900001319 A KR 900001319A KR 900012919 A KR900012919 A KR 900012919A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- alkyl
- azabicyclo
- endo
- Prior art date
Links
- 125000005605 benzo group Chemical group 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- -1 oct-3-yl Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 239000000010 aprotic solvent Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (19)
- 일반식(Ⅰ)의 화합물 및 이의 모든 광학 이성체, 호변이성 형태 및 혼합물, 및 이의 산부가염, 내염 또는 4급 유도체.상기식에서, R은 H 또는 C1-6알킬을 나타내고 ; R1및 R2는 H, 할로겐, C1-6알킬, C1-6알콕시, C1-6알킬티오, C1-6알콕시카보닐, 카복실, 하이드록시, 니트로, 시아노, 임의로 C1-4알킬 일-또는 이치환된 카바모일, 임의로 C1-4알킬 일-또는 이치환된 아미노, C1-6아실아미노, C1-4알콕시 카보닐아미노, C1-6알킬설피닐, C1-6알킬설포닐 또는 C1-6아실을 나타내며 ; R3는 H, C1-6알킬, 아릴 또는 아르알킬을 나타내거나, 부재하고 ;A는 CO, C=S, S→0 또는를 나타내며 ; B는 R3가 부재하고 B-D 결합이 단일 결합일 경우 질소를 나타내거나, 또는 탄소이며 ; D는 B-D 결합이 단일 결합일 경우, CO, CH2-CH2또는(여기에서, R4는 H, C1-6알킬, 아릴, 아르알킬, 하이드록시 또는 C1-4알콕시를 나타내고, R5는 H를 나타낸다)를 나타내거나, 또는 D-B 결합이 이중 결합일 경우, C-R이고 ; X는 산소 또는 N-R을 나타내거나, 부재하며 ; Y는 a)b)및 c)(여기에서, n은 2 또는 3이고 ; p는 동시에 또는 달리 0 또는 1이며 ; q는 0,2 또는 3이고 ; R6및 R7은, R7이 H 또는 C1-4알킬일 경우, 동시에 또는 달리 H, C1-4알킬 또는 아르알킬일 수 있거나, R6는(여기에서, R8은 H, C1-4알킬 또는 아미노를 나타낸다)일 수 있다〕로부터 선택된 염기성 그룹을 나타낸다.
- 제1항에 있어서, Y가 엔도-8-메틸-8-아자비 사이클로〔3,2,1〕옥트-3-일 또는 엔도-9-메틸-9-아자비 사이클로〔3,2,1〕옥트-3-일을 나타내고, B가 질소이며, R이 수소이고, R3가 부재하며, B-D 결합이 단일 결합이고, R1, R2, D 및 X가 제1항에서 정의한 바와 같음을 특징으로 하는 일반식(Ⅰ)의 화합물, 이의 호변이성체 및/또는 상술한 화합물의 산부가염.
- 제1항 또는 2항에 따른 일반식(Ⅰ)의 화합물의 생리학적으로 허용되는 산부가염.
- 제3항에 있어서, 염산, 브롬산, 시트로산, 타르타르산 또는 벤젠설폰산으로부터 형성된 염.
- 1,4-디하이드로-2(H)-2-옥소-3-퀴나졸린 카복실사-(엔도-8-메틸-8-아자비사이클로〔3,2,1〕옥트-3-일), 에스테르 N-(엔도-8-메틸-8-아자비사이클로〔3,2,1〕옥트-3-일), -1,4-디하이드로-2(H)-2-옥소-퀴나졸린-3-카복스아미드 7-클로로-1, 4-디하이드로-2(H)-2-옥소-퀴나졸린 카복실산-(엔도-8-아자비사이클로〔3,2,1〕옥트-3-일), 에스테르 1, 4-디하이드로-6-플루오로-2(H)-2-옥소-3-퀴나졸린 카복실산-(엔도-8-메틸-8-아자비사이클로〔3,2,1〕옥트-3-일), 에스테르 및 1, 4-디하이드로-4-하이드록시-2-(H)-2-옥소-3-퀴나졸린 카복실산-(엔도-8-메틸-8-아자비 사이클로〔3,2,1〕옥트-3-일), 에스테르로부터 선택된 일반식(Ⅰ)의 화합물, 및 이의 생리학적으로 허용되는 산부가염.
- 일반식 (Ⅱ)의 화합물을 미리 활성화제에 의해 일반식(Ⅳ)의 반응성 유도체로 활성화시키고, 이를 일반식(Ⅲ)의 화합물과 비양자성 용매중에서 -50℃ 내지 실온하에 반응시킴을 특징으로 하여, 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.상기식에서 R, R1, R2, R3, A, B, D, X 및 Y는 제1항에서 정의한 바와 같고, M은 리튬, 나트륨 및 칼륨으로부터 선택된 금속 원자이며, Q는 이탈 그룹이다.
- 제6항에 있어서, 활성화제가 n-부틸리튬, 리튬 디이소프로필아미드(LDA) 및 수소화나트륨으로부터 선택됨을 특징으로 하는 방법.
- 제6항에 있어서, 이탈 그룹이 염소, 메톡시 및 에톡시로부터 선택됨을 특징으로 하는 방법.
- B가 탄소이고, X가 산소 또는 N-R일 경우, 일반식(Ⅴ)의 화합물을 일반식(Ⅵ)의 화합물과 반응시킴을 특징으로 하여 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.상기식에서, R, R1, R2, R3, A, B, D, X 및 Y는 제1항에서 정의한 바와 같고, Q는 하이드록실이거나 제8항에서 정의한 바와 같은 그룹이다.
- 제9항에 있어서, Q가 하이드록실일 경우, 반응을 불활성 비양자성 용매중에서 적당한 축합제의 존재하에 및 임의로 촉매의 존재하에 수행함을 특징으로 하는 방법.
- 제9항에 있어서, Q가 염소일 경우, 반응을 불활성 비양자성 용매 중에서, 임의로 유기 또는 무기 산수용체의 존재하에, -10℃ 내지 선택된 용매의 비점에서 수행함을 특징으로 하는 방법.
- 제9항에 있어서, Q가 메톡시 또는 에톡시일 경우, 반응을 알코올 형태의 QOH를 공비 제거할 수 있는 불활성 용매 중에서, 임의로 촉매의 존재하에 수행함을 특징으로 하는 방법.
- 제9항에 있어서, 일반식(Ⅵ)의 화합물을 X가 산소일 경우 0 내지 80℃에서 이의 반응성 유도체로서 반응시킴을 특징으로 하는 방법.
- B가 질소이고, R이 수소이며, R3가 부재하는 경우, 일반식(Ⅶ)의 화합물을 일반식(Ⅷ)의 화합물과 비양자성 용매 중에서, 임의로 산수용체의 존재하에 20 내지 100℃에서 반응시킴을 특징으로 하여, 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.상기식에서, R1, R2, D, X 및 Y는 제1항에서 정의한 바와 같고, Q1및 Q|2는 서로 동일하거나 상이한 이탈 그룹이다.
- 제14항에 있어서, 이탈 그룹이 염소, 에톡시, 페녹시, 트리클로로메톡시 및 이미다졸릴부터 선택됨을 특징으로 하는 방법.
- 활성 성분으로서 제1항에서 정의한 바와 같은 하나 이상의 일반식(Ⅰ)의 화합물, 또는 호변이성체 또는 생리학적으로 허용되는 산부가염을 약제학적으로 허용되는 담체, 희석제 또는 부형제와 함께 함유하는 약제학적 조성물.
- 제16항에 있어서, 위장관 이상 및 특히 소화성 궤양 질병, 자극성장 증상, 경령성 변비, 분문근경련 또는 유문경련으로 고생하는 환자의 치료에 사용하기 위한 약제학적 조성물.
- 제16항에 있어서, 호흡기의 폐쇄성 급성 및 만성 경련성 이상, 특히 기관지협착, 만성 기관지염, 기종 또는 천식으로 고생하는 환자의 치료에 사용하기 위한 약제학적 조성물.
- 제16항에 있어서, 비뇨관계 및 담도의 경련성 이상으로 고생하는 환자의 치료 및 요실금의 치료에 사용하기 위한 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT19316A/89 | 1989-02-06 | ||
| IT8919316A IT1228293B (it) | 1989-02-06 | 1989-02-06 | Benzoderivati di composti eterociclici contenenti azoto. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR900012919A true KR900012919A (ko) | 1990-09-03 |
Family
ID=11156671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019900001319A KR900012919A (ko) | 1989-02-06 | 1990-02-05 | 벤조 융합된 n-함유 헤테로사이클 유도체 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5106851A (ko) |
| EP (1) | EP0382687B1 (ko) |
| JP (1) | JPH03197462A (ko) |
| KR (1) | KR900012919A (ko) |
| AT (1) | ATE132140T1 (ko) |
| AU (1) | AU623733B2 (ko) |
| CA (1) | CA2009300A1 (ko) |
| CZ (1) | CZ277886B6 (ko) |
| DE (1) | DE69024381T2 (ko) |
| DK (1) | DK0382687T3 (ko) |
| ES (1) | ES2081966T3 (ko) |
| FI (1) | FI96686C (ko) |
| GR (1) | GR3018549T3 (ko) |
| HU (2) | HUT54118A (ko) |
| IL (1) | IL93257A (ko) |
| IT (1) | IT1228293B (ko) |
| MX (1) | MX19368A (ko) |
| NO (1) | NO173500C (ko) |
| PL (1) | PL162682B1 (ko) |
| PT (1) | PT93066B (ko) |
| RU (1) | RU2040524C1 (ko) |
| YU (1) | YU21590A (ko) |
| ZA (1) | ZA90825B (ko) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1226389B (it) * | 1988-07-12 | 1991-01-15 | Angeli Inst Spa | Nuovi derivati ammidinici e guanidinici |
| GB2236751B (en) * | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US5225419A (en) * | 1989-10-14 | 1993-07-06 | John Wyeth & Brother, Limited | Certain 1,8-ethano or propano-1,4-dihydro-4-oxo-quinoline-3-carboxamides and derivatives thereof |
| HU211081B (en) * | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| JPH0692948A (ja) * | 1992-03-04 | 1994-04-05 | Snow Brand Milk Prod Co Ltd | 新規なアセタミド誘導体及びその用途 |
| JPH05310732A (ja) * | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| US5571820A (en) * | 1992-11-20 | 1996-11-05 | Taisho Pharmaceutical Co., Ltd. | Heterocyclic compound |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
| KR970701191A (ko) * | 1994-02-28 | 1997-03-17 | 우에하라 아키라 | 복소환 화합물 |
| JP3829879B2 (ja) * | 1994-05-18 | 2006-10-04 | 大正製薬株式会社 | キノリンカルボン酸誘導体 |
| EP0778835A4 (en) * | 1994-08-25 | 1999-02-03 | Univ Virginia | 7-AZABICYCLO (2.2.1) -HEPTANE AND -HEPTENE DERIVATIVES AS LIGANDS OF THE CHOLI ENERGY RECEPTORS |
| CN1226886A (zh) * | 1996-07-29 | 1999-08-25 | 法玛西雅和厄普约翰公司 | 芳基环烷甲酸酯、其用途、药物组合物和制备方法 |
| MXPA02005070A (es) * | 1999-11-18 | 2003-09-25 | Antexpharma Inc | 1-benzazepinas sustituidas y derivados de las mismas. |
| FR2801310B1 (fr) * | 1999-11-24 | 2004-04-16 | Adir | NOUVEAUX DERIVES DE DIHYDROFURO-[3,4-b]QUINOLEIN-1-ONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| US6451813B1 (en) | 2001-01-26 | 2002-09-17 | R. T. Alamo Ventures I, Llc | Treatment of gastroparesis in certain patient groups |
| EP1401830A2 (en) * | 2001-06-19 | 2004-03-31 | Warner-Lambert Company LLC | Quinazolinediones as antibacterial agents |
| MXPA04010539A (es) * | 2002-04-26 | 2005-01-25 | Nippon Shinyaku Co Ltd | Derivados de quinazolina y medicamentos que los contienen. |
| DE10255040A1 (de) * | 2002-11-26 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbaminsäureester mit anticholinerger Wirksamkeit |
| ES2338882T3 (es) * | 2003-11-24 | 2010-05-13 | Pfizer, Inc. | Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4. |
| ES2376108T3 (es) * | 2004-09-17 | 2012-03-09 | Whitehead Institute For Biomedical Research | Compuestos, composiciones y método para inhibir la toxicidad de la a-sinucleina. |
| CN104193741B (zh) * | 2007-10-01 | 2016-08-24 | 阿尔法梅根有限责任公司 | 作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物 |
| US9145396B2 (en) * | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| JP6117708B2 (ja) * | 2011-03-18 | 2017-04-19 | ジェンザイム・コーポレーション | グルコシルセラミド合成酵素阻害剤 |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2016007630A1 (en) | 2014-07-11 | 2016-01-14 | Alpharmagen, Llc | Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity |
| WO2018132829A1 (en) * | 2017-01-16 | 2018-07-19 | Drexel University | Novel glutamate transporter activators and methods using same |
| BR112023000798A2 (pt) | 2020-07-24 | 2023-02-07 | Genzyme Corp | Composições farmacêuticas compreendendo venglustat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284768A (en) * | 1980-07-02 | 1981-08-18 | American Home Products Corporation | 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| EP0126087A1 (en) * | 1982-09-24 | 1984-11-28 | Beecham Group Plc | Amino-azabicycloalkyl derivatives as dopamine antagonists |
| US4599336A (en) * | 1983-08-08 | 1986-07-08 | Hoffmann-La Roche Inc. | Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide |
| WO1985001048A1 (en) * | 1983-08-26 | 1985-03-14 | Sandoz Ag | Aromatic esters or amides of carboxylic acid and sulfonic acid |
| US4849513A (en) * | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
| GB8623142D0 (en) * | 1986-09-26 | 1986-10-29 | Beecham Group Plc | Compounds |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| JPS6463518A (en) * | 1987-09-02 | 1989-03-09 | Otsuka Pharma Co Ltd | Antiarrhythmic agent |
-
1989
- 1989-02-06 IT IT8919316A patent/IT1228293B/it active
-
1990
- 1990-01-24 CZ CS90335A patent/CZ277886B6/cs unknown
- 1990-02-02 IL IL9325790A patent/IL93257A/en not_active IP Right Cessation
- 1990-02-02 US US07/474,187 patent/US5106851A/en not_active Expired - Fee Related
- 1990-02-02 MX MX1936890A patent/MX19368A/es unknown
- 1990-02-05 HU HU90671A patent/HUT54118A/hu unknown
- 1990-02-05 AT AT90830040T patent/ATE132140T1/de not_active IP Right Cessation
- 1990-02-05 NO NO900542A patent/NO173500C/no unknown
- 1990-02-05 YU YU21590A patent/YU21590A/sh unknown
- 1990-02-05 KR KR1019900001319A patent/KR900012919A/ko not_active Application Discontinuation
- 1990-02-05 FI FI900553A patent/FI96686C/fi not_active IP Right Cessation
- 1990-02-05 PT PT93066A patent/PT93066B/pt not_active IP Right Cessation
- 1990-02-05 DK DK90830040.3T patent/DK0382687T3/da active
- 1990-02-05 ZA ZA90825A patent/ZA90825B/xx unknown
- 1990-02-05 EP EP90830040A patent/EP0382687B1/en not_active Expired - Lifetime
- 1990-02-05 JP JP2025889A patent/JPH03197462A/ja active Pending
- 1990-02-05 AU AU49086/90A patent/AU623733B2/en not_active Ceased
- 1990-02-05 ES ES90830040T patent/ES2081966T3/es not_active Expired - Lifetime
- 1990-02-05 CA CA002009300A patent/CA2009300A1/en not_active Abandoned
- 1990-02-05 PL PL28364290A patent/PL162682B1/pl unknown
- 1990-02-05 DE DE69024381T patent/DE69024381T2/de not_active Expired - Fee Related
-
1992
- 1992-05-08 RU SU925011529A patent/RU2040524C1/ru active
-
1994
- 1994-11-21 HU HU94P/P00048P patent/HU210348A9/hu unknown
-
1995
- 1995-12-28 GR GR950403474T patent/GR3018549T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR900012919A (ko) | 벤조 융합된 n-함유 헤테로사이클 유도체 | |
| Scozzafava et al. | Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties | |
| CA2329922C (en) | Imidazo pyridine derivatives which inhibit gastric acid secretion | |
| KR960006145B1 (ko) | 벤조헤테로사이클릭 화합물 | |
| US4209623A (en) | Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides | |
| JPH054968A (ja) | キノロンカルボン酸誘導体 | |
| JP3048511B2 (ja) | 新規なｎ−ピリジルカルボキサミドと誘導体、その製造方法及びそれらを含む薬剤組成物 | |
| EP0760812A1 (en) | Pharmaceutical diketopiperazine compounds | |
| JPH06506448A (ja) | 新規な活性化合物 | |
| KR0153527B1 (ko) | 아릴설폰아미드 및 이를 함유하는 약제학적 조성물 | |
| JP4817577B2 (ja) | 抗ロイコトリエン活性を持つチロシン誘導体 | |
| US4404214A (en) | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | |
| EP1003735A1 (en) | Quinolizine carboxylic acid derivatives | |
| FR2758329A1 (fr) | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique | |
| EP0009608B1 (en) | N-phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them | |
| IE50333B1 (en) | Antibacterial compositions comprising a beta-lactam-type compound and a 3-substituted propenoate | |
| EP0298134B1 (en) | Aromatic heterocyclic carboxylic acid amide derivatives, process for their preparation, and pharmaceutical composition containing same | |
| US4912135A (en) | Amide compounds | |
| US5039684A (en) | Tetrazole amide derivatives of heterocyclic alkenyl acid and their use as antiallergic substances | |
| US5578607A (en) | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists | |
| EP3210974B1 (en) | Prodrug of roflumilast | |
| JPS62108863A (ja) | ２−ピリジル酢酸誘導体、その製法およびそれを含む医薬 | |
| JP3009716B2 (ja) | 新規なカンプトテシン誘導体 | |
| JPH0323542B2 (ko) | ||
| JPH0363259A (ja) | チオホルムアミド誘導体類 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |